Previous close | 64.45 |
Open | 66.46 |
Bid | 66.54 x 3100 |
Ask | 66.93 x 4000 |
Day's range | 65.75 - 66.93 |
52-week range | 53.63 - 71.70 |
Volume | |
Avg. volume | 6,915,269 |
Market cap | 207.319B |
Beta (5Y monthly) | 0.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.36 |
Earnings date | N/A |
Forward dividend & yield | 1.44 (2.28%) |
Ex-dividend date | 24 Feb 2022 |
1y target est | 71.80 |
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Chevron Corporation (CVX), and AstraZeneca PLC (AZN).
WILMINGTON, Del., June 23, 2022--Detailed results from the positive FoCus Phase III trial in Wilson disease showed that ALXN1840, an investigational once-daily, oral medicine, met its primary endpoint demonstrating three-times greater copper mobilization from tissues compared to the standard of care (SoC) arm (Least Square Mean Difference [LSM Diff] 2.18 µmol/L; p< 0.0001), including in patients who had been treated previously for an average of 10 years.1
In the latest trading session, Astrazeneca (AZN) closed at $63.55, marking a +1.15% move from the previous day.